JBH492 / Novartis - LARVOL DELTA

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov) - P1 | N=25 | Terminated | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Terminated; Business, strategic, and development considerations and not due to any safety concerns

Monotherapy • Trial termination • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), assessing safety and efficacy in lymphoid malignancies (AACR 2024) - P1 | "The data from this phase I study suggest that targeting CCR7 with JBH492 is a promising therapeutic strategy for lymphoid malignancies with manageable hematological and non-hematological safety profile. [K.I. and S.L. contributed equally to this study.]"

Clinical • P1 data • Adult T-Cell Leukemia-Lymphoma • Chronic Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • CCR7

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov) - P1 | N=25 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: Mar 2024 ➔ Sep 2024

Monotherapy • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov) - P1 | N=25 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: Aug 2024 ➔ Mar 2024

Monotherapy • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov) - P1 | N=25 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Mar 2024 ➔ Aug 2024 | Trial primary completion date: Mar 2024 ➔ Aug 2024

Monotherapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov) - P1 | N=25 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=120 ➔ 25 | Trial completion date: Aug 2024 ➔ Mar 2024 | Trial primary completion date: Aug 2024 ➔ Mar 2024

Enrollment change • Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Novel Antibody-Drug Conjugate Targeting CCR7 in Hematologic Malignancies (ASH 2022) - P1 | "Conclusion s : Our translational data support the hypothesis that JBH492 may have the potential to become a promising first-in-class ADC for the treatment of CCR7-expressing lymphoid malignancies. The first-in-human clinical trial in patients with refractory/relapsed CLL and non-Hodgkin's lymphoma is currently ongoing (NCT04240704)."

Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CCL19 • CCR7

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jun 2023 ➔ Aug 2024 | Trial primary completion date: Jun 2023 ➔ Aug 2024

Monotherapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Novartis Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Monotherapy • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - P1; N=120; Not yet recruiting; Sponsor: Novartis Pharmaceuticals

Clinical • Monotherapy • New P1 trial